
    
      This is a pilot study to determine the safety of PCV13 administered to patients with myeloma
      before and at +7-10 days and +21-24 days after autologous hematopoietic stem cell transplant;
      and,to quantify the immune response induced by PCV13 vaccination in patients with myeloma
      when administered before and early after autologous PSCT.
    
  